Pre-made Alnuctamab benchmark antibody (Bispecific mAb with Domain Crossover, anti-TNFRSF17;CD3E therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-018

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-018 Category Tags ,

Product Details

Pre-made Alnuctamab benchmark antibody (Bispecific mAb with Domain Crossover, anti-TNFRSF17;CD3E therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Alnuctamab biosimilar, Bispecific mAb with Domain Crossover, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody

INN Name

Alnuctamab

Target

TNFRSF17,CD3E

Format

Bispecific mAb with Domain Crossover

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

IgG1;G1

VD LC

Kappa,Lambda

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Active

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;None

Year Proposed

2020

Companies

Celgene Corporation

Conditions Approved

NA

Conditions Active

Multiple myeloma

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

TNFRSF17,CD3E

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide